TL;DR
- •Spravato (esketamine) is the FIRST question that needs reframing — it's NOT typically a chronic-stop-and-taper medication like an SSRI. The right question is usually "Should I stop Spravato?" rather than "How do I taper?"
- •Spravato is dosed in defined treatment courses with maintenance schedules at clinic-based sessions (twice weekly induction → weekly → biweekly maintenance). Discontinuation is more about ending the maintenance schedule than tapering a daily dose.
- •Unlike daily antidepressants, Spravato doesn't produce classical discontinuation syndrome (no brain zaps, no flu-like symptoms). The risk of stopping is depression relapse, not withdrawal.
- •Spravato is Schedule III and requires in-clinic administration at certified REMS facilities — there's no take-home prescription, no daily pill, no dose-titration the patient controls.
- •For patients who responded to Spravato but find the clinic-based model logistically or financially difficult, at-home oral ketamine (sublingual or rapid-dissolving tablets) offers a more flexible alternative — same NMDA mechanism but different administration route, dose flexibility, and (typically) lower cost.
- •For patients who responded poorly to Spravato or experienced concerning side effects (dissociation, blood pressure spikes), evaluation by a psychiatrist with experience in ketamine-class treatments can clarify whether a different administration route or formulation might work better.
Why people decide to taper
- •Maintenance schedule has become logistically unsustainable (commute to clinic, time off work)
- •Cost — Spravato is expensive even with insurance and is not always covered
- •Dissociative side effects during sessions remain bothersome despite multiple doses
- •Blood pressure spikes that have been hard to manage
- •Original depression in long-term remission and considering tapering off treatment
- •Wanting to transition to a different administration route (oral ketamine) with more flexibility
- •Comorbid conditions that complicate continued REMS-based dosing
What withdrawal looks like
Spravato does NOT produce classical antidepressant withdrawal syndrome. There are no brain zaps, no dizziness, no flu-like symptoms. The risk of stopping is depression relapse — the underlying condition returning — rather than pharmacologic withdrawal. Patients who stop Spravato may experience their depression symptoms returning over weeks if they don't have an alternative treatment plan. Some patients also report feeling the "transition" of no-longer-having-the-treatment as a psychological adjustment, though this is distinct from pharmacologic withdrawal. Esketamine doesn't have the daily-medication-dependence physiology that SSRIs, SNRIs, or benzodiazepines have.
Typical taper timeline
Spravato discontinuation is more about transitioning OUT of the maintenance dosing schedule than tapering down. Patients in the maintenance phase (weekly or biweekly) typically space sessions further apart before stopping entirely — but this is a clinical decision about when the underlying depression is stable enough to need less treatment, not a withdrawal-management timeline. There is no "taper schedule" in the antidepressant sense.
Taper approaches
Options to bring to your prescriber. The dose-by-dose plan belongs to your prescriber, not this page.
Reframe: "Should I stop Spravato?" vs "How do I taper?"
For most Spravato patients, the question isn't how to taper but whether to stop. Esketamine is administered as discrete treatments rather than daily doses. The clinical question: is the underlying depression in stable enough remission to not need continued treatment? This is a decision made with the prescribing psychiatrist based on response duration and symptom stability.
Space maintenance sessions further apart
For patients in the maintenance phase, the typical "taper" looks like extending the interval between sessions — biweekly → monthly → bimonthly → stopping. This isn't pharmacologic taper; it's a stepped reduction in treatment frequency to see whether the depression remains in remission with less treatment.
Transition to at-home oral ketamine
For patients who responded to Spravato but find the clinic-based model logistically unsustainable, at-home oral ketamine (sublingual or rapid-dissolving tablets) offers a more flexible alternative. Same NMDA receptor mechanism but different administration route. Tovani specializes in this transition — taking Spravato responders and continuing their treatment in a home-based format that's easier to integrate with life.
Stabilize on a daily antidepressant if needed
For patients stopping Spravato who need ongoing mood support, transitioning to or starting a daily antidepressant (SSRI, SNRI, bupropion, or another agent) before stopping Spravato provides continuity. The Spravato can then be stopped without the depression returning as the new medication takes effect.
Plan for relapse-monitoring period
Regardless of the discontinuation approach, the 4-8 weeks after stopping should include close monitoring for depression relapse — more frequent symptom check-ins, attention to early warning signs, willingness to restart treatment if symptoms return. Spravato discontinuation without a relapse plan is the main risk.
What’s specific to Spravato (Esketamine)
Spravato is the S-enantiomer of ketamine (the racemic ketamine used in operating rooms and at-home oral ketamine programs is a 50/50 mix of S- and R-enantiomers). Esketamine has somewhat higher NMDA receptor affinity than racemic ketamine and was developed as the FDA-approved intranasal product. The Schedule III status and REMS program mean Spravato is administered only at certified clinics — no take-home prescriptions, no patient-controlled dosing. Standard dosing: 56mg or 84mg per session, twice weekly during induction (weeks 1-4), then weekly during weeks 5-8, then weekly or biweekly during maintenance based on response. Half-life of esketamine after intranasal administration is approximately 7-12 hours — but the antidepressant effect persists much longer than the pharmacokinetic half-life would suggest because the neuroplasticity mechanism (BDNF, synaptic remodeling) operates on a longer timescale. This is part of why Spravato doesn't require daily dosing despite the short half-life. Side effects during sessions include dissociation, blood pressure elevation, sedation — required to be monitored for 2 hours post-dose at the clinic. The REMS program is comprehensive and is a major part of why Spravato is logistically demanding compared to alternatives.
Where ketamine fits
For Spravato specifically, the "ketamine fit" framing reverses from the other entries in this category — the patient is already on a ketamine-class medication. The question is whether to continue, modify, or transition. At-home oral ketamine (sublingual or rapid-dissolving tablets) is the more flexible alternative that many Tovani patients move to from Spravato. The mechanism is the same NMDA receptor antagonism with neuroplasticity downstream effects. Key differences between Spravato and at-home oral ketamine: (1) administration route — intranasal at certified clinic vs at-home sublingual; (2) dose flexibility — Spravato is fixed at 56mg or 84mg, at-home oral allows individualized titration; (3) schedule flexibility — Spravato is fixed weekly/biweekly REMS schedule, at-home oral allows individualized cadence; (4) cost — Spravato is typically more expensive even with insurance; (5) coverage — at-home oral ketamine works for patients who can't access REMS-certified Spravato clinics. The transition is straightforward for Spravato responders because the underlying mechanism is the same — what changes is the practical administration model.
Check eligibility for ketamine therapy5-minute screening · Reviewed by a board-certified physician · FL & NJ
Frequently asked
Do I need to taper off Spravato?
Usually no — not in the traditional sense. Spravato isn't a daily medication that requires pharmacologic taper. It's administered in discrete sessions on a maintenance schedule. The "discontinuation" is typically more about extending the interval between sessions until stopping entirely. There's no withdrawal syndrome, no brain zaps, no flu-like symptoms — the risk of stopping is depression relapse, not pharmacologic withdrawal.
Will I have withdrawal symptoms when I stop Spravato?
No classical withdrawal in the antidepressant sense. Esketamine doesn't produce the daily-medication-dependence physiology of SSRIs or benzodiazepines. The main risk of stopping is the depression returning — relapse, not withdrawal. Plan for a relapse-monitoring period of 4-8 weeks after stopping, with willingness to restart treatment if symptoms return.
Can I switch from Spravato to at-home ketamine?
Yes — for many Spravato responders, this is an appealing transition. The same NMDA receptor mechanism applies; what changes is the administration route (intranasal at clinic vs at-home sublingual or rapid-dissolving tablets) and the dose flexibility. Tovani specializes in continuing ketamine treatment for Spravato responders who want a more flexible home-based model. The transition is typically straightforward because the underlying mechanism is identical.
How long should I stay on Spravato maintenance?
There's no universal answer — it depends on your individual depression history, response duration, and life context. Patients with chronic recurrent depression often benefit from longer maintenance; patients with a single episode that responded fully sometimes need shorter courses. Discuss with your prescribing psychiatrist based on your specific pattern of remission and any prior relapses.
I'm thinking of stopping Spravato. What should I plan for?
Three things. (1) A relapse-monitoring plan — close symptom check-ins for 4-8 weeks after stopping. (2) An alternative treatment plan if the depression returns — restarting Spravato, transitioning to at-home ketamine, starting an SSRI/SNRI, or other approaches. (3) A clear conversation with your prescribing psychiatrist about why you're stopping and what success vs failure looks like. Spravato discontinuation without these elements is the main risk pattern.
Never taper without prescriber coordination
Withdrawal symptoms can mimic depression or anxiety relapse, and untreated relapse can be more dangerous than withdrawal. Stopping benzodiazepines abruptly can produce seizures. Bring this page to your prescriber as a conversation starter — they translate options into your specific plan.
References
- Janik A et al. 2025, JAMA Psychiatry. Phase 4 RCT of esketamine monotherapy in treatment-resistant depression — demonstrates esketamine's antidepressant efficacy with maintenance dosing patterns appropriate for the medication's pharmacology. PMID 40601310
- Cuomo A et al. 2026, Therapeutic Advances in Psychopharmacology. 5-year observational study of intranasal esketamine in TRD — long-term dosing patterns, maintenance characteristics, and discontinuation considerations. PMID 42052285
- van Hoogdalem MW et al. 2026, Clinical and Translational Science. Esketamine nasal spray mechanism, pharmacokinetics, and clinical considerations — covers the relationship between the short pharmacokinetic half-life and longer-lasting antidepressant effect. PMID 41923438